Low-dose IL-2 Mitigates Glucocorticoid-Induced Treg Impairment and Promotes Improvement of SLE

Haotian Zhou,Xiaozhen Zhao,Ruijun Zhang,Miao,Wenwen Pei,Zijun Li,Yimin Li,Jing He,Zhanguo Li,Xiaolin Sun
DOI: https://doi.org/10.1038/s41392-023-01350-6
IF: 39.3
2023-01-01
Signal Transduction and Targeted Therapy
Abstract:Dear Editor, Previous studies have proved that regulatory T cell(Treg)insufficiency contributed to the development of autoimmune conditions including systemic lupus erythematosus(SLE).Con-ventional immunosuppressive treatment was reported to down-regulate beneficial Tregs together with pathogenic effector immune cells,which may impede a rapid achievement of optimal therapeutic effects.1,2 As the most effective and widely applied immunosuppressive medication for SLE,glucocorticoid treatment has the risk of excessive suppression of immune cell subsets.
What problem does this paper attempt to address?